Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHDX NASDAQ:NTRA NYSE:NVTA NASDAQ:RDNT NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHDXGenomic Health$63.44$64.79$50.77▼$90.18$2.38B0.91.05 million shsN/ANTRANatera$195.00+3.7%$170.70$117.27▼$196.63$25.81B1.741.17 million shs936,777 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsRDNTRadNet$82.88+2.8%$74.02$45.00▼$93.65$6.20B1.59567,816 shs734,402 shsVCYTVeracyte$35.64+2.6%$32.79$22.61▼$47.32$2.73B2.11830,735 shs680,859 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHDXGenomic Health0.00%0.00%0.00%0.00%0.00%NTRANatera+0.61%+4.79%+4.93%+33.28%+56.75%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet+0.59%+5.01%+6.60%+44.01%+19.29%VCYTVeracyte-3.74%-0.09%+2.42%+47.31%+6.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHDXGenomic Health$63.44$64.79$50.77▼$90.18$2.38B0.91.05 million shsN/ANTRANatera$195.00+3.7%$170.70$117.27▼$196.63$25.81B1.741.17 million shs936,777 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsRDNTRadNet$82.88+2.8%$74.02$45.00▼$93.65$6.20B1.59567,816 shs734,402 shsVCYTVeracyte$35.64+2.6%$32.79$22.61▼$47.32$2.73B2.11830,735 shs680,859 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHDXGenomic Health0.00%0.00%0.00%0.00%0.00%NTRANatera+0.61%+4.79%+4.93%+33.28%+56.75%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet+0.59%+5.01%+6.60%+44.01%+19.29%VCYTVeracyte-3.74%-0.09%+2.42%+47.31%+6.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHDXGenomic Health 0.00N/AN/AN/ANTRANatera 2.80Moderate Buy$197.591.33% UpsideNVTAInvitae 0.00N/AN/AN/ARDNTRadNet 3.13Buy$76.80-7.34% DownsideVCYTVeracyte 2.58Moderate Buy$40.9014.76% UpsideCurrent Analyst Ratings BreakdownLatest GHDX, NTRA, NVTA, VCYT, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/23/2025NTRANateraBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$200.00 ➝ $210.0010/20/2025VCYTVeracyteCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$40.0010/20/2025NTRANateraZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/14/2025NTRANateraCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.0010/14/2025RDNTRadNetZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025NTRANateraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RDNTRadNetWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025VCYTVeracyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/6/2025VCYTVeracyteZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025NTRANateraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RDNTRadNetWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHDXGenomic Health$394.11M6.05$1.45 per share43.76$7.48 per share8.48NTRANatera$1.70B15.77N/AN/A$9.05 per share21.55NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00RDNTRadNet$1.83B3.48$3.58 per share23.15$15.31 per share5.41VCYTVeracyte$445.76M6.29$1.06 per share33.51$15.17 per share2.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHDXGenomic Health$25.68M$1.0560.4236.88N/A12.81%19.62%14.89%N/ANTRANatera-$190.43M-$1.91N/AN/AN/A-12.89%-22.22%-15.03%11/11/2025 (Estimated)NVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/ARDNTRadNet$2.79M-$0.20N/A156.38N/A-0.78%2.41%0.82%11/10/2025 (Estimated)VCYTVeracyte$24.14M$0.33108.0049.50N/A5.50%6.07%5.53%11/4/2025 (Confirmed)Latest GHDX, NTRA, NVTA, VCYT, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025NTRANatera-$0.40N/AN/AN/A$514.55 millionN/A11/10/2025Q3 2025RDNTRadNet$0.23N/AN/AN/A$494.19 millionN/A11/4/2025Q3 2025VCYTVeracyte$0.32N/AN/AN/A$124.62 millionN/A8/10/2025Q2 2025RDNTRadNet$0.17$0.31+$0.14$0.43$488.06 million$498.23 million8/7/2025Q2 2025NTRANatera-$0.60-$0.74-$0.14-$0.74$476.84 million$546.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHDXGenomic HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHDXGenomic Health0.155.965.96NTRANateraN/A3.723.58NVTAInvitaeN/A2.392.25RDNTRadNet0.912.002.00VCYTVeracyteN/A5.435.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHDXGenomic Health93.87%NTRANatera99.90%NVTAInvitae61.28%RDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipGHDXGenomic Health31.30%NTRANatera5.63%NVTAInvitae0.74%RDNTRadNet5.60%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHDXGenomic Health82937.59 millionN/AOptionableNTRANatera4,434137.25 million129.52 millionOptionableNVTAInvitae1,700267.01 million284.37 millionOptionableRDNTRadNet11,02176.92 million72.61 millionOptionableVCYTVeracyte79078.67 million77.57 millionOptionableGHDX, NTRA, NVTA, VCYT, and RDNT HeadlinesRecent News About These CompaniesARK Investment Management LLC Has $102.72 Million Stake in Veracyte, Inc. $VCYTOctober 22 at 9:12 AM | marketbeat.comCanaccord Genuity Initiates Coverage of Veracyte (VCYT) with Hold RecommendationOctober 21 at 2:40 AM | msn.comVeracyte initiated with a Hold at CanaccordOctober 20 at 9:38 AM | msn.comVeracyte (VCYT) Receives a New Rating from Freedom Capital MarketsOctober 19, 2025 | theglobeandmail.comIs Veracyte's (VCYT) Margin Growth and New Platform Shaping Its Long-Term Diagnostic Edge?October 18, 2025 | finance.yahoo.comCannon Global Investment Management LLC Invests $419,000 in Veracyte, Inc. $VCYTOctober 18, 2025 | marketbeat.comFreedom Capital Markets Initiates Coverage of Veracyte (VCYT) with Buy RecommendationOctober 18, 2025 | msn.comStocks Generating Improved Relative Strength: VeracyteOctober 17, 2025 | msn.comAberdeen Group plc Buys Shares of 181,923 Veracyte, Inc. $VCYTOctober 17, 2025 | marketbeat.comVeracyte initiated with a Buy at Freedom CapitalOctober 16, 2025 | msn.comDo You Believe in the Upside Potential of Veracyte (VCYT)October 16, 2025 | msn.comVeracyte (VCYT) Crossed Above the 20-Day Moving Average: What That Means for InvestorsOctober 16, 2025 | zacks.comAEGON ASSET MANAGEMENT UK Plc Has $8.21 Million Stock Holdings in Veracyte, Inc. $VCYTOctober 16, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Stock Crosses Above 50-Day Moving Average - What's Next?October 16, 2025 | marketbeat.comVeracyte to Release Third Quarter 2025 Financial Results on November 4, 2025October 15, 2025 | businesswire.comVeracyte's (VCYT) Sell (D+) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Upgraded to "Strong-Buy" at Zacks ResearchOctober 8, 2025 | marketbeat.comInsider Selling: Veracyte (NASDAQ:VCYT) Insider Sells 8,349 Shares of StockOctober 8, 2025 | insidertrades.comVeracyte (NASDAQ:VCYT) Insider Sells 8,349 SharesOctober 7, 2025 | marketbeat.comThis Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your RadarOctober 7, 2025 | zacks.comVeracyte (VCYT): Reassessing Valuation After New BALANCE Trial Data Highlights Decipher’s Clinical ImpactOctober 6, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Defense Stocks Surging as Ukraine Tensions DeepenBy Dan Schmidt | October 5, 20255 Stocks Congress Quietly Bought in Q3—Should You Follow?By Thomas Hughes | October 10, 2025Rocket Lab's Electron: The Quiet Workhorse Powering MomentumBy Ryan Hasson | October 2, 2025General Dynamics Hits New Highs: Why It Might Keep ClimbingBy Jeffrey Neal Johnson | October 2, 2025Big Gains Alert: These 3 Tech Stocks Are Surging This MonthBy Chris Markoch | October 10, 2025GHDX, NTRA, NVTA, VCYT, and RDNT Company DescriptionsGenomic Health NASDAQ:GHDXGenomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.Natera NASDAQ:NTRA$195.00 +6.98 (+3.71%) Closing price 04:00 PM EasternExtended Trading$196.50 +1.50 (+0.77%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.RadNet NASDAQ:RDNT$82.88 +2.25 (+2.79%) Closing price 04:00 PM EasternExtended Trading$82.50 -0.38 (-0.46%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$35.64 +0.89 (+2.56%) Closing price 04:00 PM EasternExtended Trading$35.66 +0.02 (+0.07%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
